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Fusobacterium necrophorum leukotoxoid vaccine for prevention of liver
abscesses
Abstract
The efficacy of Fusobacterium necrophorum crude leukotoxoid vaccine to immunize and protect steers
against experimentally induced liver abscesses was evaluated. The vaccine consisted of cell-free culture
supernatant of a high leukotoxin-producing strain of F. necrophorum, inactivated with formalin and
homogenized with an oil emulsion adjuvant. Vaccine was injected subcutaneously on days 0 and 21.
Blood samples were collected weekly to monitor immune response. Three weeks after the second
vaccination, steers were injected intraportally with F. necrophorum culture to induce liver abscesses.
Three weeks later (day 63), steers were euthanatized and necropsied; livers were examined, and
protection was assessed. Anti-leukotoxin antibody titers in the control steers generally did not differ from
the baseline (week 0) titers. The titers in the vaccinated groups increased, more so after the second
injection, and the increase was generally dose dependent. At necropsy, all steers in the control group had
liver abscesses. In the vaccinated groups, two out of five steers in the 1.0 ml group and one each in the
2.0, 5.0, and 2.25 ml (concentrated) groups had liver abscesses. The difference suggests a protective
effect of antileukotoxin antibodies against experimentally induced liver abscesses.
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leukotoxin antibodies against experimentally
induced liver abscesses.

Summary
The
efficacy
of
Fusobacterium
necrophorum crude leukotoxoid vaccine to
immunize and protect steers against experimentally induced liver abscesses was evaluated. The vaccine consisted of cell-free
culture supernatant of a high leukotoxinproducing strain of F. necrophorum, inactivated with formalin and homogenized with an
oil emulsion adjuvant. Vaccine was injected
subcutaneously on days 0 and 21. Blood
samples were collected weekly to monitor
immune response. Three weeks after the
second vaccination, steers were injected
intraportally with F. necrophorum culture to
induce liver abscesses. Three weeks later (day
63), steers were euthanatized and necropsied;
livers were examined, and protection was
assessed. Anti-leukotoxin antibody titers in
the control steers generally did not differ
from the baseline (week 0) titers. The titers
in the vaccinated groups increased, more so
after the second injection, and the increase
was generally dose dependent. At necropsy,
all steers in the control group had liver
abscesses. In the vaccinated groups, two out
of five steers in the 1.0 ml group and one
each in the 2.0, 5.0, and 2.25 ml (concentrated) groups had liver abscesses. The difference suggests a protective effect of anti-
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Introduction
Liver abscesses are of economic concern
to the feedlot industry because they cause
liver condemnation, reduced feed efficiency,
and reduced weight gain. Fusobacterium
necrophorum, is the primary causative agent
of liver abscesses. The incidence of liver
abscesses averages 18 to 32% in feedlot
cattle and is related to feeding high grain
diets. Rapid ruminal fermentation of grain in
the rumen results in ruminal acidosis and
rumenitis, which are considered to be predisposing factors for liver abscesses.
Fusobacterium necrophorum, a normal
inhabitant of the rumen, colonizes the ruminal
epithelial wall, reaches the liver via the portal
circulation, and sets up infection. The ability
of F. necrophorum to colonize ruminal epithelium and establish infection in the liver is
attributed mainly to a potent leukotoxin that
is toxic to leukocytes, macrophages, ruminal
epithelial cells, and hepatocytes. Therefore,
immunizing the animal against the toxin may
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prevent the onset of liver abscesses. Our
objective was to determine the efficacy of F.
necrophorum leukotoxoid vaccine to immunize steers and to provide protection against
experimentally induced liver abscesses.

The leukotoxin concentration in the
original culture supernatant was 27,020
units/ml. In the culture supernatant concentrated 5.2-fold, the leukotoxin concentration
was 54,040 units/ml. Apparently, the process
of concentration reduced the leukotoxin
activity. Therefore, 2.25 ml of the concentrated supernatant was used to equal the
leukotoxin concentration in the 4.5 ml dose.

Experimental Procedures
Fusobacterium necrophorum, A25, a
high leukotoxin producing strain, previously
isolated from a liver abscess was used to
prepare the vaccine, which consisted of cellfree supernatant (original or concentrated
5.2 fold) inactivated by adding formalin and
homogenized with an oil emulsion adjuvant.
The leukotoxicity of the original and concentrated culture supernatants, before and after
formalin inactivation, was determined.

Antibody titers in the control steers injected with phosphate-buffered saline generally did not differ from the baseline throughout the 6-week sampling period. The titers in
the vaccinated steers increased (P<.01) following the first vaccination and increased
much more after the second injection (Figure
1). A significant treatment x week interaction (P < .01) occurred. Generally, the antibody titers appeared to be related to the dose
of leukotoxoid, with the 1.0 ml dose eliciting
the lowest antibody titers and the 5.0 ml dose
eliciting the highest. The purpose of using the
concentrated supernatant was to determine
whether concentrating the culture supernatant
to reduce the injection volume would alter its
immunogenicity or protective effect. Apparently, concentrating the culture supernatant
reduced its immunogenicity as evidenced by
lower antibody titers.

Twenty-five Holstein steers (mean body
weight 860 lb), fed ad libitum a diet of alfalfa
hay, were assigned randomly to five groups:
control; three doses (1.0, 2.0, and 5.0 ml) of
the culture supernatant; and a dose of the
concentrated supernatant (2.25 ml) equivalent to the leukotoxin concentration in 4.5 ml
of the original culture supernatant (Table 1).
Each steer in the control group received 4.5
ml of phosphate buffer saline mixed with
adjuvant. All injections were given subcutaneously on days 0 and 21.

At necropsy, all five steers in the control
group had liver abscesses as compared to two
out of five steers in the 1.0-ml-vaccinated
group and one each in the 2.0, 5.0, and 2.25
ml (concentrated) groups (Table 2). Based
on Fisher’s exact test (2-tail), the incidence of
liver abscesses was lower (P<0.01) in the
vaccinated groups (all four doses) than in the
control. Steers that developed abscesses
(n=10) had lower anti-leukotoxin titers
(P<0.05) during wk 1 to 6 than those steers

Jugular blood samples were collected at
weekly intervals after the first vaccination to
monitor the immune response. Serum samples were assayed for anti-leukotoxin antibody titers. Three weeks after the second
vaccination, steers were inoculated intraportally by an ultrasound-guided, percutaneous, catheterization procedure with F.
necrophorum to induce liver abscesses
Steers were euthanatized 21 days after the
intraportal challenge and examined for abscesses and other gross lesions in the liver
and other organs.
Results and Discussion
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(n=15) that did not develop abscesses in the
liver, regardless of the treatment (Figure 2).

degree of protection against experimentally
induced liver abscesses. However, further
studies are required to determine the efficacy
of the vaccine in feedlot cattle with naturally
developing liver abscesses.

Our results indicate that F. necrophorum
culture supernatant was capable’ of eliciting
anti-leukotoxin immunity that provided some

Table 1.

Treatment Groups and Leukotoxin Concentration in the Culture
Supernatant

Treatment
Control

Culture
Concentrated Phosphate
a
Supernatant Supernatant BufferedSaline (ml)
(ml)
(ml)
—
—
4.5

Adjuvant
(ml)
.5

Leukotoxin
Titer per
Dose
—

Culture
supernatant, 1.0 ml

0.9

—

.l

24,318

Culture
supernatant, 2.0 ml

1.8

—

.2

48,636

Culture
supernatant, 5.0 ml

4.5

—

.5

121,590

.5

121,590

Concentrated
supernatant, 2.25 ml
a

2.25

2.25

Culture supernatant concentrated 5.2-fold

Table 2. Experimental Induction of Liver Abscesses in Control or Vaccinated Steers
Liver Abscesses
Treatment

No. of Steers

Necropsy

a

Incidence (%)

Control

5

5/5

100

Culture supernatant, 1.0 ml

5

2/5

40

Culture supernatant, 2.0 ml

5

1/5

20

Culture supernatant, 5.0 ml

5

1/5

20

1/5

20

b
5
Concentrated supernatant, 2.25 ml
a
Fisher’s exact test (2-tail), control vs. vaccinated P < .01.
b
Culture supernatant concentrated 5.2-fold.
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Figure 1.

Serum Leukotoxin-Neutralizing Antibody Titers in Controls or Steers
Vaccinated with 1.0, 2.0, or 5.0 ml Culture Supernatant and 2.25 ml of the
Concentrated (C) Supernatant. SEM = 1.6, Treatment Effect P<.0l, Week
Effect P<.0l, and Treatment x Week Interaction P<.05.

Figure 2.

Serum Leukotoxin-Neutralizing Antibody Titers in Steers that Developed
(N=10) or Did Not Develop (N=15) Liver Abscesses. SEM=1.4, Abscess
Effect P<.05, Week Effect P<.01).
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